Details of the Drug

General Information of Drug (ID: DMOWZ6B)

Drug Name
Fluconazole
Synonyms
Afungil; Alflucoz; Baten; Beagyne; Biocanol; Biozolene; Canzol; Cryptal; Diflazon; Diflucan; Dimycon; Elazor; FCZ; FLCZ; Flucazol; FlucoLich; Flucobeta; Fluconazol; Fluconazolum; Flucostat; Flukezol; Flunazul; Flunizol; Fluzone; Forcan; Fuconal; Fungata; Lavisa; Loitin; Mutum; Neofomiral; Oxifugol; Oxifungol; Pritenzol; Solacap; Syscan; TPF; Triflucan; Zemyc; Zoltec; Zonal; AbZ Brand of Fluconazole; Aliud Brand of Fluconazole; Alpharma Brand of Fluconazole; Apo Fluconazole; Apotex Brand of Fluconazole; Armstrong Brand of Fluconazole; Betapharm Brand of Fluconazole; Chemia Brand of Fluconazole; Ct Arzneimittel Brand of Fluconazole; Effik Brand of Fluconazole; Fluc Hexal; Fluconazol AL; Fluconazol AbZ; Fluconazol Isis; Fluconazol Stada; Fluconazol [Spanish]; Fluconazol ratiopharm; Fluconazol von ct; Fluconazolum [Latin]; Hexal Brand of Fluconazole; Lesvi Brand of Fluconazole; Lichtenstein Brand of Fluconazole; Mack Brand of Fluconazole; Pfizer Brand of Fluconazole; Pfleger Brand of Fluconazole; Ratiopharm Brand of Fluconazole; SAT Brand of Fluconazole; Silanes Brand of Fluconazole; Stada Brand of Fluconazole; Vita Brand of Fluconazole; F0677; Fluconazole in combination with MGCD290; UK 49858; UK49858; Alfumet (TN); Apo-Fluconazole; Ct-Arzneimittel Brand of Fluconazole; DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER; DRG-0005; Diflucan (TN); Fluconazol-Isis; Fluconazol-ratiopharm; Fluconazole & Bovine Lactoferrin; Fluconazole & Human recombinant granulocyte colony stimulating factor; Fluconazole & hGCSF; Fluconazole in dextrose 5% in plastic container; Flucytosine & Nyotran; GL663142 & Fluconazole; KS-1059; Trican (TN); UK-49858; DIFLUCAN IN SODIUM CHLORIDE 0.9%; DIFLUCAN IN SODIUM CHLORIDE 0.9%IN PLASTIC CONTAINER; Fluconazole in sodium chloride 0.9%; Fluconazole in sodium chloride 0.9% in plastic container; Flucytosine & Nyotran(Liposomal Nystatin); XMP.284 & Fluconazole; XMP.366 & Fluconazole; XMP.391 & Fluconazole; Diflucan, Trican, Alfumet, Fluconazole; Fluconazole & MC-510,011; Fluconazole (JAN/USAN/INN); Fluconazole [USAN:INN:BAN:JAN]; 2,4-Difluoro-alpha,alpha-bis(1H-1,2,4-triazol-1-ylmethyl)benzyl alcohol; 2,4-difluoro-,1-bis(1H-1,2,4-triazol-1-ylmethyl)benzyl alcohol; 2-(2,4-DIFLUOROPHENYL)-1,3-DI(1H-1,2,4-TRIAZOL-1-YL)PROPAN-2-OL; 2-(2,4-Difluoro-phenyl)-1,3-bis-[1,2,4]triazol-1-yl-propan-2-ol; 2-(2,4-Difluorophenyl)-1,3-bis(1H-1,2,4-triazol-1-yl)-2-propanol; 2-(2,4-Difluorophenyl)-1,3-bis(1H-1,2,4-triazol-1-yl)propan-2-ol; 2-(2,4-Difluorophenyl)-1,3-di-1H-1,2,4-triazol-1-ylpropan-2-ol; 2-(2,4-difluorophenyl)-1,3-bis(1,2,4-triazol-1-yl)propan-2-ol
Indication
Disease Entry ICD 11 Status REF
Fungal infection 1F29-1F2F Approved [1]
Therapeutic Class
Antifungal Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 306.27
Topological Polar Surface Area (xlogp) 0.4
Rotatable Bond Count (rotbonds) 5
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 7
ADMET Property
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 3 h [2]
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 3: high solubility and low permeability [3]
Bioavailability
The bioavailability of drug is 90% [2]
Clearance
The renal clearance of drug is 14.7 +/- 3.7 mL/min [2]
Elimination
In normal volunteers, fluconazole is cleared primarily by renal excretion, with approximately 80% of the administered dose measured in the urine as unchanged drug [2]
Half-life
The concentration or amount of drug in body reduced by one-half in 20 - 50 hours [2]
Metabolism
The drug is metabolized via the liver [4]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 9.3285 micromolar/kg/day [5]
Unbound Fraction
The unbound fraction of drug in plasma is 0.89% [6]
Vd
The volume of distribution (Vd) of drug is 39 L [2]
Water Solubility
The ability of drug to dissolve in water is measured as 1 mg/mL [3]
Chemical Identifiers
Formula
C13H12F2N6O
IUPAC Name
2-(2,4-difluorophenyl)-1,3-bis(1,2,4-triazol-1-yl)propan-2-ol
Canonical SMILES
C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O
InChI
InChI=1S/C13H12F2N6O/c14-10-1-2-11(12(15)3-10)13(22,4-20-8-16-6-18-20)5-21-9-17-7-19-21/h1-3,6-9,22H,4-5H2
InChIKey
RFHAOTPXVQNOHP-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
3365
ChEBI ID
CHEBI:46081
CAS Number
86386-73-4
DrugBank ID
DB00196
TTD ID
D09LNI
VARIDT ID
DR00578
INTEDE ID
DR0704
ACDINA ID
D00280

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Candida Cytochrome P450 51 (Candi ERG11) TTTSOUD CP51_CANAL Modulator [7]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 2C9 (CYP2C9)
Main DME 		DE5IED8 CP2C9_HUMAN Substrate [8]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Fluconazole
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Pentamidine DMHZJCG Moderate Increased risk of prolong QT interval by the combination of Fluconazole and Pentamidine. Fungal infection [1F29-1F2F] [25]
Terbinafine DMI6HUW Moderate Decreased metabolism of Fluconazole caused by Terbinafine mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [25]
Miconazole DMPMYE8 Moderate Decreased metabolism of Fluconazole caused by Miconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [26]
Ketoconazole DMPZI3Q Moderate Increased risk of prolong QT interval by the combination of Fluconazole and Ketoconazole. Fungal infection [1F29-1F2F] [25]
Coadministration of a Drug Treating the Disease Different from Fluconazole (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Increased risk of hepatotoxicity by the combination of Fluconazole and Remdesivir. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [27]
Methylergonovine DMBEX4O Moderate Decreased metabolism of Fluconazole caused by Methylergonovine mediated inhibition of CYP450 enzyme. Abortion [JA00] [28]
Tretinoin DM49DUI Major Decreased metabolism of Fluconazole caused by Tretinoin mediated inhibition of CYP450 enzyme. Acne vulgaris [ED80] [29]
Glimepiride DM5FSJA Major Decreased metabolism of Fluconazole caused by Glimepiride mediated inhibition of CYP450 enzyme. Acute diabete complication [5A2Y] [30]
Repaglinide DM5SXUV Moderate Decreased metabolism of Fluconazole caused by Repaglinide mediated inhibition of CYP450 enzyme. Acute diabete complication [5A2Y] [31]
Glibenclamide DM8JXPZ Major Decreased metabolism of Fluconazole caused by Glibenclamide mediated inhibition of CYP450 enzyme. Acute diabete complication [5A2Y] [30]
Tolazamide DMIHRNA Major Decreased metabolism of Fluconazole caused by Tolazamide mediated inhibition of CYP450 enzyme. Acute diabete complication [5A2Y] [30]
Nateglinide DMLK2QH Moderate Decreased metabolism of Fluconazole caused by Nateglinide mediated inhibition of CYP450 enzyme. Acute diabete complication [5A2Y] [32]
Acetohexamide DMR6N7H Major Decreased metabolism of Fluconazole caused by Acetohexamide mediated inhibition of CYP450 enzyme. Acute diabete complication [5A2Y] [30]
Glipizide DMZA5PQ Major Decreased metabolism of Fluconazole caused by Glipizide mediated inhibition of CYP450 enzyme. Acute diabete complication [5A2Y] [30]
Thioguanine DM7NKEV Moderate Increased risk of hepatotoxicity by the combination of Fluconazole and Thioguanine. Acute myeloid leukaemia [2A60] [33]
Ivosidenib DM8S6T7 Major Decreased metabolism of Fluconazole caused by Ivosidenib mediated inhibition of CYP450 enzyme. Acute myeloid leukaemia [2A60] [34]
Midostaurin DMI6E0R Moderate Decreased metabolism of Fluconazole caused by Midostaurin mediated inhibition of CYP450 enzyme. Acute myeloid leukaemia [2A60] [35]
Idarubicin DMM0XGL Moderate Increased risk of prolong QT interval by the combination of Fluconazole and Idarubicin. Acute myeloid leukaemia [2A60] [25]
Daunorubicin DMQUSBT Moderate Increased risk of prolong QT interval by the combination of Fluconazole and Daunorubicin. Acute myeloid leukaemia [2A60] [25]
Arn-509 DMT81LZ Moderate Increased risk of prolong QT interval by the combination of Fluconazole and Arn-509. Acute myeloid leukaemia [2A60] [32]
Gilteritinib DMWQ4MZ Moderate Decreased metabolism of Fluconazole caused by Gilteritinib mediated inhibition of CYP450 enzyme. Acute myeloid leukaemia [2A60] [32]
Terfenadine DM4KLPT Major Decreased metabolism of Fluconazole caused by Terfenadine mediated inhibition of CYP450 enzyme. Allergic/hypersensitivity disorder [4A80-4A8Z] [36]
Loratadine DMF3AN7 Minor Decreased metabolism of Fluconazole caused by Loratadine mediated inhibition of CYP450 enzyme. Allergic/hypersensitivity disorder [4A80-4A8Z] [37]
Tacrine DM51FY6 Moderate Increased risk of ventricular arrhythmias by the combination of Fluconazole and Tacrine. Alzheimer disease [8A20] [25]
Galantamine DMEO794 Moderate Increased risk of ventricular arrhythmias by the combination of Fluconazole and Galantamine. Alzheimer disease [8A20] [25]
Rivastigmine DMG629M Moderate Increased risk of ventricular arrhythmias by the combination of Fluconazole and Rivastigmine. Alzheimer disease [8A20] [25]
Donepezil DMIYG7Z Minor Decreased metabolism of Fluconazole caused by Donepezil mediated inhibition of CYP450 enzyme. Alzheimer disease [8A20] [38]
Metronidazole DMTIVEN Minor Increased risk of prolong QT interval by the combination of Fluconazole and Metronidazole. Amoebiasis [1A36] [27]
Ranolazine DM0C9IL Major Decreased metabolism of Fluconazole caused by Ranolazine mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [39]
Bepridil DM0RKS4 Major Increased risk of prolong QT interval by the combination of Fluconazole and Bepridil. Angina pectoris [BA40] [25]
Dronedarone DMA8FS5 Major Increased risk of prolong QT interval by the combination of Fluconazole and Dronedarone. Angina pectoris [BA40] [25]
Nifedipine DMSVOZT Moderate Decreased metabolism of Fluconazole caused by Nifedipine mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [40]
Bedaquiline DM3906J Major Increased risk of prolong QT interval by the combination of Fluconazole and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [41]
Buspirone DMBS632 Moderate Decreased metabolism of Fluconazole caused by Buspirone mediated inhibition of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [42]
Alprazolam DMC7XDN Major Decreased metabolism of Fluconazole caused by Alprazolam mediated inhibition of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [43]
Hydroxyzine DMF8Y74 Moderate Increased risk of prolong QT interval by the combination of Fluconazole and Hydroxyzine. Anxiety disorder [6B00-6B0Z] [25]
Clobazam - Lundbeck DMW1OQ0 Moderate Decreased metabolism of Fluconazole caused by Clobazam - Lundbeck mediated inhibition of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [44]
Promazine DMZAL7W Moderate Increased risk of prolong QT interval by the combination of Fluconazole and Promazine. Appearance/behaviour symptom [MB23] [25]
Cilostazol DMZMSCT Major Decreased metabolism of Fluconazole caused by Cilostazol mediated inhibition of CYP450 enzyme. Arterial occlusive disease [BD40] [32]
Voriconazole DMAOL2S Moderate Increased risk of prolong QT interval by the combination of Fluconazole and Voriconazole. Aspergillosis [1F20] [45]
Posaconazole DMUL5EW Moderate Increased risk of prolong QT interval by the combination of Fluconazole and Posaconazole. Aspergillosis [1F20] [25]
Levalbuterol DM5YBO1 Moderate Increased risk of ventricular arrhythmias by the combination of Fluconazole and Levalbuterol. Asthma [CA23] [46]
Montelukast DMD157S Moderate Decreased metabolism of Fluconazole caused by Montelukast mediated inhibition of CYP450 enzyme. Asthma [CA23] [47]
Terbutaline DMD4381 Moderate Increased risk of ventricular arrhythmias by the combination of Fluconazole and Terbutaline. Asthma [CA23] [48]
Pirbuterol DMI5678 Moderate Increased risk of prolong QT interval by the combination of Fluconazole and Pirbuterol. Asthma [CA23] [48]
Isoetharine DMITSEH Moderate Increased risk of ventricular arrhythmias by the combination of Fluconazole and Isoetharine. Asthma [CA23] [48]
Budesonide DMJIBAW Moderate Decreased metabolism of Fluconazole caused by Budesonide mediated inhibition of CYP450 enzyme. Asthma [CA23] [49]
Salbutamol DMN9CWF Moderate Increased risk of prolong QT interval by the combination of Fluconazole and Salbutamol. Asthma [CA23] [46]
Formoterol DMSOURV Moderate Increased risk of ventricular arrhythmias by the combination of Fluconazole and Formoterol. Asthma [CA23] [48]
Pimecrolimus DMZLGRB Minor Decreased metabolism of Fluconazole caused by Pimecrolimus mediated inhibition of CYP450 enzyme. Atopic eczema [EA80] [50]
Atomoxetine DM5L6HI Moderate Increased risk of prolong QT interval by the combination of Fluconazole and Atomoxetine. Attention deficit hyperactivity disorder [6A05] [25]
Lisdexamfetamine DM6W8V5 Moderate Increased risk of prolong QT interval by the combination of Fluconazole and Lisdexamfetamine. Attention deficit hyperactivity disorder [6A05] [32]
Desipramine DMT2FDC Moderate Decreased metabolism of Fluconazole caused by Desipramine mediated inhibition of CYP450 enzyme. Attention deficit hyperactivity disorder [6A05] [51]
Ofloxacin DM0VQN3 Moderate Increased risk of prolong QT interval by the combination of Fluconazole and Ofloxacin. Bacterial infection [1A00-1C4Z] [52]
Ciprofloxacin XR DM2NLS9 Moderate Increased risk of prolong QT interval by the combination of Fluconazole and Ciprofloxacin XR. Bacterial infection [1A00-1C4Z] [25]
Erythromycin DM4K7GQ Major Decreased metabolism of Fluconazole caused by Erythromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [32]
Sulfamethoxazole DMB08GE Minor Increased risk of prolong QT interval by the combination of Fluconazole and Sulfamethoxazole. Bacterial infection [1A00-1C4Z] [25]
Sparfloxacin DMB4HCT Major Increased risk of prolong QT interval by the combination of Fluconazole and Sparfloxacin. Bacterial infection [1A00-1C4Z] [52]
Gemifloxacin DMHT34O Moderate Increased risk of prolong QT interval by the combination of Fluconazole and Gemifloxacin. Bacterial infection [1A00-1C4Z] [52]
Norfloxacin DMIZ6W2 Moderate Increased risk of prolong QT interval by the combination of Fluconazole and Norfloxacin. Bacterial infection [1A00-1C4Z] [52]
Rabeprazole DMMZXIW Moderate Decreased metabolism of Fluconazole caused by Rabeprazole mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [32]
Moxifloxacin DMU8V4S Major Increased risk of prolong QT interval by the combination of Fluconazole and Moxifloxacin. Bacterial infection [1A00-1C4Z] [53]
Troleandomycin DMUZNIG Moderate Decreased metabolism of Fluconazole caused by Troleandomycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [26]
Lomefloxacin DMVRH9C Moderate Increased risk of prolong QT interval by the combination of Fluconazole and Lomefloxacin. Bacterial infection [1A00-1C4Z] [25]
Telithromycin DMZ4P3A Moderate Increased risk of prolong QT interval by the combination of Fluconazole and Telithromycin. Bacterial infection [1A00-1C4Z] [25]
Retigabine DMGNYIH Moderate Increased risk of prolong QT interval by the combination of Fluconazole and Retigabine. Behcet disease [4A62] [25]
Cariprazine DMJYDVK Moderate Decreased metabolism of Fluconazole caused by Cariprazine mediated inhibition of CYP450 enzyme. Bipolar disorder [6A60] [54]
Pexidartinib DMS2J0Z Major Increased risk of hepatotoxicity by the combination of Fluconazole and Pexidartinib. Bone/articular cartilage neoplasm [2F7B] [55]
Loperamide DMOJZQ9 Moderate Increased risk of prolong QT interval by the combination of Fluconazole and Loperamide. Bowel habit change [ME05] [56]
Eribulin DM1DX4Q Moderate Increased risk of prolong QT interval by the combination of Fluconazole and Eribulin. Breast cancer [2C60-2C6Y] [25]
Ixabepilone DM2OZ3G Moderate Decreased metabolism of Fluconazole caused by Ixabepilone mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [57]
Lapatinib DM3BH1Y Moderate Decreased metabolism of Fluconazole caused by Lapatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [58]
HKI-272 DM6QOVN Major Decreased metabolism of Fluconazole caused by HKI-272 mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [59]
LY2835219 DM93VBZ Moderate Decreased metabolism of Fluconazole caused by LY2835219 mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [60]
Esterified estrogens DM9KZDO Moderate Decreased metabolism of Fluconazole caused by Esterified estrogens mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [61]
Palbociclib DMD7L94 Moderate Decreased metabolism of Fluconazole caused by Palbociclib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [32]
Quinestrol DMJ6H1Z Moderate Decreased metabolism of Fluconazole caused by Quinestrol mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [61]
Tamoxifen DMLB0EZ Moderate Increased risk of prolong QT interval by the combination of Fluconazole and Tamoxifen. Breast cancer [2C60-2C6Y] [25]
Cabazitaxel DMPAZHC Moderate Decreased metabolism of Fluconazole caused by Cabazitaxel mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [62]
Toremifene DMQYUWG Major Increased risk of prolong QT interval by the combination of Fluconazole and Toremifene. Breast cancer [2C60-2C6Y] [25]
Bosutinib DMTI8YE Major Decreased metabolism of Fluconazole caused by Bosutinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [27]
Estradiol DMUNTE3 Moderate Decreased metabolism of Fluconazole caused by Estradiol mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [61]
Grepafloxacin DMGLX0T Major Increased risk of prolong QT interval by the combination of Fluconazole and Grepafloxacin. Bronchitis [CA20] [52]
Sotalol DML60TN Major Increased risk of prolong QT interval by the combination of Fluconazole and Sotalol. Cardiac arrhythmia [BC9Z] [25]
Dofetilide DMPN1TW Major Increased risk of prolong QT interval by the combination of Fluconazole and Dofetilide. Cardiac arrhythmia [BC9Z] [25]
Atorvastatin DMF28YC Major Decreased metabolism of Fluconazole caused by Atorvastatin mediated inhibition of CYP450 enzyme. Cardiovascular disease [BA00-BE2Z] [63]
Macitentan DMP79A1 Moderate Decreased metabolism of Fluconazole caused by Macitentan mediated inhibition of CYP450 enzyme. Cardiovascular disease [BA00-BE2Z] [64]
Olodaterol DM62B78 Moderate Increased risk of prolong QT interval by the combination of Fluconazole and Olodaterol. Chronic obstructive pulmonary disease [CA22] [48]
Vilanterol DMF5EK1 Moderate Increased risk of prolong QT interval by the combination of Fluconazole and Vilanterol. Chronic obstructive pulmonary disease [CA22] [46]
Salmeterol DMIEU69 Moderate Increased risk of prolong QT interval by the combination of Fluconazole and Salmeterol. Chronic obstructive pulmonary disease [CA22] [48]
Indacaterol DMQJHR7 Moderate Increased risk of prolong QT interval by the combination of Fluconazole and Indacaterol. Chronic obstructive pulmonary disease [CA22] [48]
Arformoterol DMYM974 Moderate Increased risk of prolong QT interval by the combination of Fluconazole and Arformoterol. Chronic obstructive pulmonary disease [CA22] [48]
Anisindione DM2C48U Major Decreased metabolism of Fluconazole caused by Anisindione mediated inhibition of CYP450 enzyme. Coagulation defect [3B10] [65]
Irinotecan DMP6SC2 Moderate Decreased metabolism of Fluconazole caused by Irinotecan mediated inhibition of CYP450 enzyme. Colorectal cancer [2B91] [25]
Oxaliplatin DMQNWRD Moderate Increased risk of prolong QT interval by the combination of Fluconazole and Oxaliplatin. Colorectal cancer [2B91] [25]
Isoproterenol DMK7MEY Moderate Increased risk of prolong QT interval by the combination of Fluconazole and Isoproterenol. Conduction disorder [BC63] [46]
Drospirenone DM1A9W3 Moderate Decreased metabolism of Fluconazole caused by Drospirenone mediated inhibition of CYP450 enzyme. Contraceptive management [QA21] [61]
Levonorgestrel DM1DP7T Moderate Decreased metabolism of Fluconazole caused by Levonorgestrel mediated inhibition of CYP450 enzyme. Contraceptive management [QA21] [61]
Ulipristal DMBNI20 Minor Decreased metabolism of Fluconazole caused by Ulipristal mediated inhibition of CYP450 enzyme. Contraceptive management [QA21] [32]
Etonogestrel DMKA8J4 Moderate Decreased metabolism of Fluconazole caused by Etonogestrel mediated inhibition of CYP450 enzyme. Contraceptive management [QA21] [61]
Levobupivacaine DM783CH Moderate Decreased metabolism of Fluconazole caused by Levobupivacaine mediated inhibition of CYP450 enzyme. Corneal disease [9A76-9A78] [32]
Halothane DM80OZ5 Moderate Increased risk of prolong QT interval by the combination of Fluconazole and Halothane. Corneal disease [9A76-9A78] [25]
Propofol DMB4OLE Moderate Increased risk of prolong QT interval by the combination of Fluconazole and Propofol. Corneal disease [9A76-9A78] [66]
Sevoflurane DMC9O43 Moderate Increased risk of prolong QT interval by the combination of Fluconazole and Sevoflurane. Corneal disease [9A76-9A78] [25]
Lidocaine DML4ZOT Moderate Decreased metabolism of Fluconazole caused by Lidocaine mediated inhibition of CYP450 enzyme. Corneal disease [9A76-9A78] [26]
Cocaine DMSOX7I Moderate Decreased metabolism of Fluconazole caused by Cocaine mediated inhibition of CYP450 enzyme. Corneal disease [9A76-9A78] [26]
Ropivacaine DMSPJG2 Minor Decreased metabolism of Fluconazole caused by Ropivacaine mediated inhibition of CYP450 enzyme. Corneal disease [9A76-9A78] [67]
Alfentanil DMVO0UB Major Decreased metabolism of Fluconazole caused by Alfentanil mediated inhibition of CYP450 enzyme. Corneal disease [9A76-9A78] [68]
Probucol DMVZQ2M Moderate Increased risk of prolong QT interval by the combination of Fluconazole and Probucol. Coronary atherosclerosis [BA80] [25]
Nimodipine DMQ0RKZ Moderate Decreased metabolism of Fluconazole caused by Nimodipine mediated inhibition of CYP450 enzyme. Coronary vasospastic disease [BA85] [40]
Methadone DMTW6IU Major Increased risk of prolong QT interval by the combination of Fluconazole and Methadone. Cough [MD12] [25]
Clofazimine DMEBOFW Moderate Increased risk of prolong QT interval by the combination of Fluconazole and Clofazimine. Crohn disease [DD70] [69]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Fluconazole and Pasireotide. Cushing syndrome [5A70] [25]
Osilodrostat DMIJC9X Moderate Increased risk of prolong QT interval by the combination of Fluconazole and Osilodrostat. Cushing syndrome [5A70] [32]
Ivacaftor DMZC1HS Major Decreased metabolism of Fluconazole caused by Ivacaftor mediated inhibition of CYP450 enzyme. Cystic fibrosis [CA25] [32]
Rivaroxaban DMQMBZ1 Moderate Decreased metabolism of Fluconazole caused by Rivaroxaban mediated inhibition of CYP450 enzyme. Deep vein thrombosis [BD71] [27]
Aprepitant DM053KT Moderate Decreased metabolism of Fluconazole caused by Aprepitant mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [70]
Sertraline DM0FB1J Moderate Increased risk of prolong QT interval by the combination of Fluconazole and Sertraline. Depression [6A70-6A7Z] [25]
Trimipramine DM1SC8M Moderate Decreased metabolism of Fluconazole caused by Trimipramine mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [51]
Imipramine DM2NUH3 Moderate Decreased metabolism of Fluconazole caused by Imipramine mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [51]
Fluoxetine DM3PD2C Moderate Increased risk of prolong QT interval by the combination of Fluconazole and Fluoxetine. Depression [6A70-6A7Z] [25]
Nortriptyline DM4KDYJ Moderate Decreased metabolism of Fluconazole caused by Nortriptyline mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [51]
Vilazodone DM4LECQ Moderate Decreased metabolism of Fluconazole caused by Vilazodone mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [71]
Nefazodone DM4ZS8M Moderate Decreased metabolism of Fluconazole caused by Nefazodone mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [26]
Escitalopram DMFK9HG Major Increased risk of prolong QT interval by the combination of Fluconazole and Escitalopram. Depression [6A70-6A7Z] [25]
OPC-34712 DMHG57U Major Decreased metabolism of Fluconazole caused by OPC-34712 mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [72]
Clomipramine DMINRKW Moderate Decreased metabolism of Fluconazole caused by Clomipramine mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [51]
Trazodone DMK1GBJ Moderate Increased risk of prolong QT interval by the combination of Fluconazole and Trazodone. Depression [6A70-6A7Z] [73]
Amitriptyline DMK7F9S Moderate Decreased metabolism of Fluconazole caused by Amitriptyline mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [51]
Amoxapine DMKITQE Moderate Increased risk of prolong QT interval by the combination of Fluconazole and Amoxapine. Depression [6A70-6A7Z] [25]
Mirtazapine DML53ZJ Moderate Decreased metabolism of Fluconazole caused by Mirtazapine mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [74]
Protriptyline DMNHTZI Moderate Increased risk of prolong QT interval by the combination of Fluconazole and Protriptyline. Depression [6A70-6A7Z] [25]
Doxepin DMPI98T Moderate Increased risk of prolong QT interval by the combination of Fluconazole and Doxepin. Depression [6A70-6A7Z] [25]
Maprotiline DMPWB7T Moderate Increased risk of prolong QT interval by the combination of Fluconazole and Maprotiline. Depression [6A70-6A7Z] [25]
Venlafaxine DMR6QH0 Moderate Increased risk of prolong QT interval by the combination of Fluconazole and Venlafaxine. Depression [6A70-6A7Z] [27]
Polatuzumab vedotin DMF6Y0L Moderate Decreased metabolism of Fluconazole caused by Polatuzumab vedotin mediated inhibition of CYP450 enzyme. Diffuse large B-cell lymphoma [2A81] [75]
[3H]estrone-3-sulphate DMGPF0N Moderate Decreased metabolism of Fluconazole caused by [3H]estrone-3-sulphate mediated inhibition of CYP450 enzyme. Discovery agent [N.A.] [76]
Tetrabenazine DMYWQ0O Moderate Increased risk of prolong QT interval by the combination of Fluconazole and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [25]
Ospemifene DMC4GEI Major Decreased metabolism of Fluconazole caused by Ospemifene mediated inhibition of CYP450 enzyme. Dyspareunia [GA12] [77]
Deutetrabenazine DMUPFLI Moderate Increased risk of prolong QT interval by the combination of Fluconazole and Deutetrabenazine. Dystonic disorder [8A02] [78]
Ingrezza DMVPLNC Moderate Increased risk of prolong QT interval by the combination of Fluconazole and Ingrezza. Dystonic disorder [8A02] [79]
Diazepam DM08E9O Moderate Decreased metabolism of Fluconazole caused by Diazepam mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [80]
Zonisamide DM0DTF7 Moderate Decreased metabolism of Fluconazole caused by Zonisamide mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [81]
Mephenytoin DM5UGDK Major Decreased metabolism of Fluconazole caused by Mephenytoin mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [82]
Ethosuximide DMDZ9LT Moderate Decreased metabolism of Fluconazole caused by Ethosuximide mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [26]
Tiagabine DMKSQG0 Moderate Decreased metabolism of Fluconazole caused by Tiagabine mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [26]
Stiripentol DMMSDOY Moderate Decreased metabolism of Fluconazole caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [32]
Phenytoin DMNOKBV Major Decreased metabolism of Fluconazole caused by Phenytoin mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [82]
Fosphenytoin DMOX3LB Major Decreased metabolism of Fluconazole caused by Fosphenytoin mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [82]
Brivaracetam DMSEPK8 Minor Decreased metabolism of Fluconazole caused by Brivaracetam mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [32]
Ethotoin DMXWOCP Major Decreased metabolism of Fluconazole caused by Ethotoin mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [82]
Phenobarbital DMXZOCG Minor Decreased metabolism of Fluconazole caused by Phenobarbital mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [83]
Carbamazepine DMZOLBI Moderate Decreased metabolism of Fluconazole caused by Carbamazepine mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [26]
Cannabidiol DM0659E Minor Decreased metabolism of Fluconazole caused by Cannabidiol mediated inhibition of CYP450 enzyme. Epileptic encephalopathy [8A62] [32]
Nicardipine DMCDYW7 Moderate Decreased metabolism of Fluconazole caused by Nicardipine mediated inhibition of CYP450 enzyme. Essential hypertension [BA00] [40]
Bay 80-6946 DMLOS5R Moderate Decreased metabolism of Fluconazole caused by Bay 80-6946 mediated inhibition of CYP450 enzyme. Follicular lymphoma [2A80] [84]
Tazemetostat DMWP1BH Major Decreased metabolism of Fluconazole caused by Tazemetostat mediated inhibition of CYP450 enzyme. Follicular lymphoma [2A80] [85]
Solifenacin DMG592Q Moderate Decreased metabolism of Fluconazole caused by Solifenacin mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [86]
Mirabegron DMS1GYT Minor Decreased metabolism of Fluconazole caused by Mirabegron mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [87]
Tolterodine DMSHPW8 Moderate Decreased metabolism of Fluconazole caused by Tolterodine mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [88]
Darifenacin DMWXLYZ Moderate Decreased metabolism of Fluconazole caused by Darifenacin mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [89]
Dexlansoprazole DM1DBV5 Moderate Decreased metabolism of Fluconazole caused by Dexlansoprazole mediated inhibition of CYP450 enzyme. Gastro-oesophageal reflux disease [DA22] [32]
Omeprazole DM471KJ Moderate Decreased metabolism of Fluconazole caused by Omeprazole mediated inhibition of CYP450 enzyme. Gastro-oesophageal reflux disease [DA22] [32]
Pantoprazole DMSVOCZ Moderate Decreased metabolism of Fluconazole caused by Pantoprazole mediated inhibition of CYP450 enzyme. Gastro-oesophageal reflux disease [DA22] [32]
Cisapride DMY7PED Major Decreased metabolism of Fluconazole caused by Cisapride mediated inhibition of CYP450 enzyme. Gastro-oesophageal reflux disease [DA22] [90]
Ripretinib DM958QB Moderate Decreased metabolism of Fluconazole caused by Ripretinib mediated inhibition of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [27]
Sunitinib DMCBJSR Moderate Increased risk of prolong QT interval by the combination of Fluconazole and Sunitinib. Gastrointestinal stromal tumour [2B5B] [25]
Avapritinib DMK2GZX Major Decreased metabolism of Fluconazole caused by Avapritinib mediated inhibition of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [32]
Colchicine DM2POTE Major Decreased metabolism of Fluconazole caused by Colchicine mediated inhibition of CYP450 enzyme. Gout [FA25] [91]
Ergotamine DMKR3C5 Moderate Decreased metabolism of Fluconazole caused by Ergotamine mediated inhibition of CYP450 enzyme. Headache [8A80-8A84] [92]
Eplerenone DMF0NQR Major Decreased metabolism of Fluconazole caused by Eplerenone mediated inhibition of CYP450 enzyme. Heart failure [BD10-BD1Z] [93]
Carvedilol DMHTEAO Moderate Decreased metabolism of Fluconazole caused by Carvedilol mediated inhibition of CYP450 enzyme. Heart failure [BD10-BD1Z] [94]
Torasemide DMXKJ6C Moderate Decreased metabolism of Fluconazole caused by Torasemide mediated inhibition of CYP450 enzyme. Heart failure [BD10-BD1Z] [95]
Simeprevir DMLUA9D Major Decreased metabolism of Fluconazole caused by Simeprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [27]
Daclatasvir DMSFK9V Moderate Decreased metabolism of Fluconazole caused by Daclatasvir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [27]
Brentuximab vedotin DMWLC57 Moderate Increased risk of hepatotoxicity by the combination of Fluconazole and Brentuximab vedotin. Hodgkin lymphoma [2B30] [96]
MK-1439 DM215WE Minor Decreased metabolism of Fluconazole caused by MK-1439 mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [97]
Delavirdine DM3NF5G Moderate Decreased metabolism of Fluconazole caused by Delavirdine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [26]
Nevirapine DM6HX9B Moderate Decreased metabolism of Fluconazole caused by Nevirapine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [26]
Cobicistat DM6L4H2 Moderate Decreased metabolism of Fluconazole caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [98]
Tipranavir DM8HJX6 Moderate Decreased metabolism of Fluconazole caused by Tipranavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [99]
Efavirenz DMC0GSJ Major Increased risk of prolong QT interval by the combination of Fluconazole and Efavirenz. Human immunodeficiency virus disease [1C60-1C62] [100]
Dolutegravir DMCZGRE Minor Decreased metabolism of Fluconazole caused by Dolutegravir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [101]
Saquinavir DMG814N Major Increased risk of prolong QT interval by the combination of Fluconazole and Saquinavir. Human immunodeficiency virus disease [1C60-1C62] [102]
Lopinavir DMITQS0 Moderate Increased risk of prolong QT interval by the combination of Fluconazole and Lopinavir. Human immunodeficiency virus disease [1C60-1C62] [25]
Rilpivirine DMJ0QOW Moderate Increased metabolism of Fluconazole caused by Rilpivirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [103]
Amprenavir DMLMXE0 Minor Decreased metabolism of Fluconazole caused by Amprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [104]
Maraviroc DMTL94F Moderate Decreased metabolism of Fluconazole caused by Maraviroc mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [105]
Ritonavir DMU764S Minor Decreased metabolism of Fluconazole caused by Ritonavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [106]
Simvastatin DM30SGU Major Decreased metabolism of Fluconazole caused by Simvastatin mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [63]
Fluvastatin DM4MDJY Moderate Decreased metabolism of Fluconazole caused by Fluvastatin mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [107]
Lovastatin DM9OZWQ Major Decreased metabolism of Fluconazole caused by Lovastatin mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [63]
Mipomersen DMGSRN1 Major Increased risk of hepatotoxicity by the combination of Fluconazole and Mipomersen. Hyper-lipoproteinaemia [5C80] [108]
Teriflunomide DMQ2FKJ Major Increased risk of hepatotoxicity by the combination of Fluconazole and Teriflunomide. Hyper-lipoproteinaemia [5C80] [25]
BMS-201038 DMQTAGO Major Decreased metabolism of Fluconazole caused by BMS-201038 mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [27]
Aliskiren DM1BV7W Moderate Decreased metabolism of Fluconazole caused by Aliskiren mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [25]
Losartan DM72JXH Moderate Decreased metabolism of Fluconazole caused by Losartan mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [109]
Nisoldipine DM7ISKJ Moderate Decreased metabolism of Fluconazole caused by Nisoldipine mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [40]
Levamlodipine DM92S6N Moderate Decreased metabolism of Fluconazole caused by Levamlodipine mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [40]
Isradipine DMA5XGH Moderate Decreased metabolism of Fluconazole caused by Isradipine mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [40]
Verapamil DMA7PEW Moderate Decreased metabolism of Fluconazole caused by Verapamil mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [40]
Diltiazem DMAI7ZV Moderate Decreased metabolism of Fluconazole caused by Diltiazem mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [40]
Amlodipine DMBDAZV Moderate Decreased metabolism of Fluconazole caused by Amlodipine mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [40]
Felodipine DMOSW35 Moderate Decreased metabolism of Fluconazole caused by Felodipine mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [40]
Hydrochlorothiazide DMUSZHD Minor Decreased renal excretion of Fluconazole caused by Hydrochlorothiazide. Hypertension [BA00-BA04] [27]
Tolvaptan DMIWFRL Moderate Decreased metabolism of Fluconazole caused by Tolvaptan mediated inhibition of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [110]
Fludrocortisone DMUDIR8 Moderate Decreased metabolism of Fluconazole caused by Fludrocortisone mediated inhibition of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [26]
Pirfenidone DM6VZFQ Moderate Decreased metabolism of Fluconazole caused by Pirfenidone mediated inhibition of CYP450 enzyme. Idiopathic interstitial pneumonitis [CB03] [32]
Retapamulin DM9JXB7 Minor Decreased metabolism of Fluconazole caused by Retapamulin mediated inhibition of CYP450 enzyme. Impetigo [1B72] [111]
Lesinurad DMUR64T Moderate Decreased metabolism of Fluconazole caused by Lesinurad mediated inhibition of CYP450 enzyme. Inborn purine/pyrimidine/nucleotide metabolism error [5C55] [112]
Suvorexant DM0E6S3 Major Decreased metabolism of Fluconazole caused by Suvorexant mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [113]
Ramelteon DM7IW9J Moderate Decreased metabolism of Fluconazole caused by Ramelteon mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [114]
Eszopiclone DM8RZ9H Moderate Decreased metabolism of Fluconazole caused by Eszopiclone mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [115]
Tasimelteon DMLOQ1V Moderate Decreased metabolism of Fluconazole caused by Tasimelteon mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [116]
ITI-007 DMUQ1DO Major Decreased metabolism of Fluconazole caused by ITI-007 mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [117]
Polyethylene glycol DM4I1JP Moderate Increased risk of ventricular arrhythmias by the combination of Fluconazole and Polyethylene glycol. Irritable bowel syndrome [DD91] [32]
Phenolphthalein DM5SICT Moderate Increased risk of ventricular arrhythmias by the combination of Fluconazole and Phenolphthalein. Irritable bowel syndrome [DD91] [25]
Eluxadoline DMYZ0P1 Moderate Decreased metabolism of Fluconazole caused by Eluxadoline mediated inhibition of CYP450 enzyme. Irritable bowel syndrome [DD91] [118]
Naloxegol DML0B41 Major Decreased metabolism of Fluconazole caused by Naloxegol mediated inhibition of CYP450 enzyme. Large intestine motility disorder [DB32] [32]
Methotrexate DM2TEOL Moderate Increased risk of hepatotoxicity by the combination of Fluconazole and Methotrexate. Leukaemia [2A60-2B33] [32]
Pemigatinib DM819JF Major Decreased metabolism of Fluconazole caused by Pemigatinib mediated inhibition of CYP450 enzyme. Liver cancer [2C12] [32]
Testosterone DM7HUNW Moderate Decreased metabolism of Fluconazole caused by Testosterone mediated inhibition of CYP450 enzyme. Low bone mass disorder [FB83] [26]
Crizotinib DM4F29C Major Increased risk of prolong QT interval by the combination of Fluconazole and Crizotinib. Lung cancer [2C25] [119]
Brigatinib DM7W94S Major Decreased metabolism of Fluconazole caused by Brigatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [27]
Ceritinib DMB920Z Major Increased risk of prolong QT interval by the combination of Fluconazole and Ceritinib. Lung cancer [2C25] [25]
Lurbinectedin DMEFRTZ Major Decreased metabolism of Fluconazole caused by Lurbinectedin mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [120]
PF-06463922 DMKM7EW Moderate Decreased metabolism of Fluconazole caused by PF-06463922 mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [121]
Pralsetinib DMWU0I2 Moderate Decreased metabolism of Fluconazole caused by Pralsetinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [122]
Capmatinib DMYCXKL Moderate Decreased metabolism of Fluconazole caused by Capmatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [123]
Selpercatinib DMZR15V Major Decreased metabolism of Fluconazole caused by Selpercatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [32]
Lumefantrine DM29GAD Major Increased risk of prolong QT interval by the combination of Fluconazole and Lumefantrine. Malaria [1F40-1F45] [27]
Halofantrine DMOMK1V Major Increased risk of prolong QT interval by the combination of Fluconazole and Halofantrine. Malaria [1F40-1F45] [124]
Chloroquine DMSI5CB Major Increased risk of prolong QT interval by the combination of Fluconazole and Chloroquine. Malaria [1F40-1F45] [125]
Hydroxychloroquine DMSIVND Major Increased risk of prolong QT interval by the combination of Fluconazole and Hydroxychloroquine. Malaria [1F40-1F45] [125]
Quinine DMSWYF5 Moderate Decreased metabolism of Fluconazole caused by Quinine mediated inhibition of CYP450 enzyme. Malaria [1F40-1F45] [27]
Primaquine DMWQ16I Moderate Increased risk of prolong QT interval by the combination of Fluconazole and Primaquine. Malaria [1F40-1F45] [25]
Inotuzumab ozogamicin DMAC130 Moderate Increased risk of prolong QT interval by the combination of Fluconazole and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [32]
Calaspargase pegol DMQZBXI Moderate Increased risk of hepatotoxicity by the combination of Fluconazole and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [126]
Idelalisib DM602WT Moderate Increased risk of hepatotoxicity by the combination of Fluconazole and Idelalisib. Mature B-cell leukaemia [2A82] [127]
GDC-0199 DMH0QKA Major Decreased metabolism of Fluconazole caused by GDC-0199 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [27]
IPI-145 DMWA24P Moderate Decreased metabolism of Fluconazole caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [128]
Arsenic trioxide DM61TA4 Major Increased risk of ventricular arrhythmias by the combination of Fluconazole and Arsenic trioxide. Mature B-cell lymphoma [2A85] [129]
Acalabrutinib DM7GCVW Major Decreased metabolism of Fluconazole caused by Acalabrutinib mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [130]
Clofarabine DMCVJ86 Moderate Increased risk of hepatotoxicity by the combination of Fluconazole and Clofarabine. Mature B-cell lymphoma [2A85] [131]
Ibrutinib DMHZCPO Major Decreased metabolism of Fluconazole caused by Ibrutinib mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [132]
Vincristine DMINOX3 Moderate Decreased metabolism of Fluconazole caused by Vincristine mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [26]
Ponatinib DMYGJQO Moderate Decreased metabolism of Fluconazole caused by Ponatinib mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [133]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Fluconazole and Vemurafenib. Melanoma [2C30] [25]
Selumetinib DMC7W6R Major Decreased metabolism of Fluconazole caused by Selumetinib mediated inhibition of CYP450 enzyme. Melanoma [2C30] [134]
LGX818 DMNQXV8 Major Decreased metabolism of Fluconazole caused by LGX818 mediated inhibition of CYP450 enzyme. Melanoma [2C30] [135]
Estrone DM5T6US Moderate Decreased metabolism of Fluconazole caused by Estrone mediated inhibition of CYP450 enzyme. Menopausal disorder [GA30] [61]
Dienestrol DMBSXI0 Moderate Decreased metabolism of Fluconazole caused by Dienestrol mediated inhibition of CYP450 enzyme. Menopausal disorder [GA30] [76]
Conjugated estrogens DMLT0E1 Moderate Decreased metabolism of Fluconazole caused by Conjugated estrogens mediated inhibition of CYP450 enzyme. Menopausal disorder [GA30] [61]
Ethinyl estradiol DMODJ40 Moderate Decreased metabolism of Fluconazole caused by Ethinyl estradiol mediated inhibition of CYP450 enzyme. Menopausal disorder [GA30] [76]
Nitisinone DMVS9WQ Moderate Decreased metabolism of Fluconazole caused by Nitisinone mediated inhibition of CYP450 enzyme. Metabolism inborn error [5C50] [25]
Methysergide DM1EF73 Moderate Decreased metabolism of Fluconazole caused by Methysergide mediated inhibition of CYP450 enzyme. Migraine [8A80] [28]
Dihydroergotamine DM5IKUF Moderate Decreased metabolism of Fluconazole caused by Dihydroergotamine mediated inhibition of CYP450 enzyme. Migraine [8A80] [92]
Ubrogepant DM749I3 Moderate Decreased metabolism of Fluconazole caused by Ubrogepant mediated inhibition of CYP450 enzyme. Migraine [8A80] [136]
Rimegepant DMHOAUG Moderate Decreased metabolism of Fluconazole caused by Rimegepant mediated inhibition of CYP450 enzyme. Migraine [8A80] [137]
Eletriptan DMW649X Moderate Decreased metabolism of Fluconazole caused by Eletriptan mediated inhibition of CYP450 enzyme. Migraine [8A80] [138]
Flibanserin DM70DTN Major Decreased metabolism of Fluconazole caused by Flibanserin mediated inhibition of CYP450 enzyme. Mood disorder [6A60-6E23] [139]
Midazolam DMXOELT Major Decreased metabolism of Fluconazole caused by Midazolam mediated inhibition of CYP450 enzyme. Mood/affect symptom [MB24] [43]
Panobinostat DM58WKG Major Increased risk of prolong QT interval by the combination of Fluconazole and Panobinostat. Multiple myeloma [2A83] [140]
Thalidomide DM70BU5 Moderate Increased risk of ventricular arrhythmias by the combination of Fluconazole and Thalidomide. Multiple myeloma [2A83] [27]
Fingolimod DM5JVAN Major Increased risk of ventricular arrhythmias by the combination of Fluconazole and Fingolimod. Multiple sclerosis [8A40] [25]
Ozanimod DMT6AM2 Major Increased risk of ventricular arrhythmias by the combination of Fluconazole and Ozanimod. Multiple sclerosis [8A40] [141]
Deflazacort DMV0RNS Major Decreased metabolism of Fluconazole caused by Deflazacort mediated inhibition of CYP450 enzyme. Muscular dystrophy [8C70] [32]
Rifabutin DM1YBHK Moderate Decreased metabolism of Fluconazole caused by Rifabutin mediated inhibition of CYP450 enzyme. Mycobacterium infection [1B10-1B21] [142]
Romidepsin DMT5GNL Moderate Increased risk of prolong QT interval by the combination of Fluconazole and Romidepsin. Mycosis fungoides [2B01] [25]
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Fluconazole caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [32]
Nilotinib DM7HXWT Major Increased risk of prolong QT interval by the combination of Fluconazole and Nilotinib. Myeloproliferative neoplasm [2A20] [25]
Ruxolitinib DM7Q98D Major Decreased metabolism of Fluconazole caused by Ruxolitinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [32]
Imatinib DM7RJXL Moderate Decreased metabolism of Fluconazole caused by Imatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [143]
Dasatinib DMJV2EK Moderate Decreased metabolism of Fluconazole caused by Dasatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [144]
Modafinil DMYILBE Minor Decreased metabolism of Fluconazole caused by Modafinil mediated inhibition of CYP450 enzyme. Narcolepsy [7A20] [27]
Droperidol DM0DXA8 Major Increased risk of prolong QT interval by the combination of Fluconazole and Droperidol. Nausea/vomiting [MD90] [25]
Prochlorperazine DM53SRA Moderate Increased risk of prolong QT interval by the combination of Fluconazole and Prochlorperazine. Nausea/vomiting [MD90] [25]
Promethazine DM6I5GR Moderate Increased risk of prolong QT interval by the combination of Fluconazole and Promethazine. Nausea/vomiting [MD90] [25]
Palonosetron DMBHMOX Moderate Increased risk of prolong QT interval by the combination of Fluconazole and Palonosetron. Nausea/vomiting [MD90] [25]
Granisetron DMIUW25 Moderate Decreased metabolism of Fluconazole caused by Granisetron mediated inhibition of CYP450 enzyme. Nausea/vomiting [MD90] [26]
Dolasetron DMMG26Z Major Increased risk of prolong QT interval by the combination of Fluconazole and Dolasetron. Nausea/vomiting [MD90] [25]
Ondansetron DMOTQ1I Moderate Increased risk of prolong QT interval by the combination of Fluconazole and Ondansetron. Nausea/vomiting [MD90] [25]
Entrectinib DMMPTLH Major Decreased metabolism of Fluconazole caused by Entrectinib mediated inhibition of CYP450 enzyme. Non-small cell lung cancer [2C25] [27]
Sibutramine DMFJTDI Minor Decreased metabolism of Fluconazole caused by Sibutramine mediated inhibition of CYP450 enzyme. Obesity [5B80-5B81] [145]
Levomethadyl Acetate DM06HG5 Major Decreased metabolism of Fluconazole caused by Levomethadyl Acetate mediated inhibition of CYP450 enzyme. Opioid use disorder [6C43] [146]
Lofexidine DM1WXA6 Moderate Increased risk of prolong QT interval by the combination of Fluconazole and Lofexidine. Opioid use disorder [6C43] [25]
S-297995 DM26IH8 Moderate Decreased metabolism of Fluconazole caused by S-297995 mediated inhibition of CYP450 enzyme. Opioid use disorder [6C43] [32]
Valdecoxib DMAY7H4 Moderate Decreased metabolism of Fluconazole caused by Valdecoxib mediated inhibition of CYP450 enzyme. Osteoarthritis [FA00-FA05] [147]
Diclofenac DMPIHLS Moderate Decreased metabolism of Fluconazole caused by Diclofenac mediated inhibition of CYP450 enzyme. Osteoarthritis [FA00-FA05] [27]
Olaparib DM8QB1D Major Decreased metabolism of Fluconazole caused by Olaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [27]
Rucaparib DM9PVX8 Moderate Increased risk of prolong QT interval by the combination of Fluconazole and Rucaparib. Ovarian cancer [2C73] [25]
Dextropropoxyphene DM23HCX Moderate Increased risk of prolong QT interval by the combination of Fluconazole and Dextropropoxyphene. Pain [MG30-MG3Z] [148]
Butorphanol DM5KYPJ Major Decreased metabolism of Fluconazole caused by Butorphanol mediated inhibition of CYP450 enzyme. Pain [MG30-MG3Z] [149]
Buprenorphine DMPRI8G Moderate Decreased metabolism of Fluconazole caused by Buprenorphine mediated inhibition of CYP450 enzyme. Pain [MG30-MG3Z] [150]
Hydrocodone DMQ2JO5 Major Decreased metabolism of Fluconazole caused by Hydrocodone mediated inhibition of CYP450 enzyme. Pain [MG30-MG3Z] [151]
Oxycodone DMXLKHV Major Decreased metabolism of Fluconazole caused by Oxycodone mediated inhibition of CYP450 enzyme. Pain [MG30-MG3Z] [27]
Triclabendazole DMPWGBR Moderate Increased risk of prolong QT interval by the combination of Fluconazole and Triclabendazole. Parasitic worm infestation [1F90] [25]
Istradefylline DM20VSK Moderate Decreased metabolism of Fluconazole caused by Istradefylline mediated inhibition of CYP450 enzyme. Parkinsonism [8A00] [152]
Pimavanserin DMR7IVC Moderate Increased risk of prolong QT interval by the combination of Fluconazole and Pimavanserin. Parkinsonism [8A00] [153]
Bromocriptine DMVE3TK Moderate Decreased metabolism of Fluconazole caused by Bromocriptine mediated inhibition of CYP450 enzyme. Parkinsonism [8A00] [26]
Apomorphine DMX38HQ Moderate Increased risk of prolong QT interval by the combination of Fluconazole and Apomorphine. Parkinsonism [8A00] [25]
Esomeprazole DM7BN0X Moderate Decreased metabolism of Fluconazole caused by Esomeprazole mediated inhibition of CYP450 enzyme. Peptic ulcer [DA61] [32]
Famotidine DMRL3AB Moderate Increased risk of prolong QT interval by the combination of Fluconazole and Famotidine. Peptic ulcer [DA61] [27]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Fluconazole and Macimorelin. Pituitary gland disorder [5A60-5A61] [154]
Lefamulin DME6G97 Major Increased risk of prolong QT interval by the combination of Fluconazole and Lefamulin. Pneumonia [CA40] [155]
Prednisone DM2HG4X Moderate Decreased metabolism of Fluconazole caused by Prednisone mediated inhibition of CYP450 enzyme. Postoperative inflammation [1A00-CA43] [26]
Betamethasone DMAHJEF Moderate Decreased metabolism of Fluconazole caused by Betamethasone mediated inhibition of CYP450 enzyme. Postoperative inflammation [1A00-CA43] [26]
Hydrocortisone DMGEMB7 Moderate Decreased metabolism of Fluconazole caused by Hydrocortisone mediated inhibition of CYP450 enzyme. Postoperative inflammation [1A00-CA43] [26]
Ergonovine DM0VEC1 Moderate Decreased metabolism of Fluconazole caused by Ergonovine mediated inhibition of CYP450 enzyme. Postpartum haemorrhage [JA43] [28]
Lonafarnib DMGM2Z6 Major Decreased metabolism of Fluconazole caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [156]
Ritodrine DM4V6RL Moderate Increased risk of ventricular arrhythmias by the combination of Fluconazole and Ritodrine. Preterm labour/delivery [JB00] [48]
Progesterone DMUY35B Moderate Decreased metabolism of Fluconazole caused by Progesterone mediated inhibition of CYP450 enzyme. Preterm labour/delivery [JB00] [61]
Degarelix DM3O8QY Moderate Increased risk of prolong QT interval by the combination of Fluconazole and Degarelix. Prostate cancer [2C82] [32]
ABIRATERONE DM8V75C Moderate Increased risk of prolong QT interval by the combination of Fluconazole and ABIRATERONE. Prostate cancer [2C82] [32]
Nilutamide DMFN07X Moderate Increased risk of prolong QT interval by the combination of Fluconazole and Nilutamide. Prostate cancer [2C82] [32]
Enzalutamide DMGL19D Moderate Increased risk of prolong QT interval by the combination of Fluconazole and Enzalutamide. Prostate cancer [2C82] [32]
Flutamide DMK0O7U Moderate Increased risk of prolong QT interval by the combination of Fluconazole and Flutamide. Prostate cancer [2C82] [32]
Relugolix DMK7IWL Moderate Increased risk of prolong QT interval by the combination of Fluconazole and Relugolix. Prostate cancer [2C82] [32]
Darolutamide DMV7YFT Minor Decreased metabolism of Fluconazole caused by Darolutamide mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [157]
Bicalutamide DMZMSPF Moderate Increased risk of prolong QT interval by the combination of Fluconazole and Bicalutamide. Prostate cancer [2C82] [32]
Tamsulosin DM5QF9V Moderate Decreased metabolism of Fluconazole caused by Tamsulosin mediated inhibition of CYP450 enzyme. Prostate hyperplasia [GA90] [158]
Silodosin DMJSBT6 Moderate Decreased metabolism of Fluconazole caused by Silodosin mediated inhibition of CYP450 enzyme. Prostate hyperplasia [GA90] [159]
Dutasteride DMQ4TJK Moderate Decreased metabolism of Fluconazole caused by Dutasteride mediated inhibition of CYP450 enzyme. Prostate hyperplasia [GA90] [160]
Finasteride DMWV3TZ Moderate Decreased metabolism of Fluconazole caused by Finasteride mediated inhibition of CYP450 enzyme. Prostate hyperplasia [GA90] [26]
Alfuzosin DMZVMKF Moderate Increased risk of prolong QT interval by the combination of Fluconazole and Alfuzosin. Prostate hyperplasia [GA90] [25]
Levomepromazine DMIKFEL Moderate Increased risk of prolong QT interval by the combination of Fluconazole and Levomepromazine. Psychotic disorder [6A20-6A25] [25]
Fluphenazine DMIT8LX Moderate Increased risk of prolong QT interval by the combination of Fluconazole and Fluphenazine. Psychotic disorder [6A20-6A25] [25]
Triflupromazine DMKFQJP Moderate Increased risk of prolong QT interval by the combination of Fluconazole and Triflupromazine. Psychotic disorder [6A20-6A25] [25]
Selexipag DMAHSU0 Moderate Decreased metabolism of Fluconazole caused by Selexipag mediated inhibition of UGT. Pulmonary hypertension [BB01] [27]
Ambrisentan DMD1QXW Minor Decreased metabolism of Fluconazole caused by Ambrisentan mediated inhibition of CYP450 enzyme. Pulmonary hypertension [BB01] [161]
Bosentan DMIOGBU Moderate Decreased metabolism of Fluconazole caused by Bosentan mediated inhibition of CYP450 enzyme. Pulmonary hypertension [BB01] [27]
Everolimus DM8X2EH Major Decreased metabolism of Fluconazole caused by Everolimus mediated inhibition of CYP450 enzyme. Renal cell carcinoma [2C90] [162]
Axitinib DMGVH6N Moderate Decreased metabolism of Fluconazole caused by Axitinib mediated inhibition of CYP450 enzyme. Renal cell carcinoma [2C90] [32]
Temsirolimus DMS104F Moderate Decreased metabolism of Fluconazole caused by Temsirolimus mediated inhibition of CYP450 enzyme. Renal cell carcinoma [2C90] [163]
Sorafenib DMS8IFC Moderate Increased risk of prolong QT interval by the combination of Fluconazole and Sorafenib. Renal cell carcinoma [2C90] [25]
Gatifloxacin DMSL679 Major Increased risk of prolong QT interval by the combination of Fluconazole and Gatifloxacin. Respiratory infection [CA07-CA4Z] [53]
Meloxicam DM2AR7L Moderate Decreased metabolism of Fluconazole caused by Meloxicam mediated inhibition of CYP450 enzyme. Rheumatoid arthritis [FA20] [27]
Upadacitinib DM32B5U Moderate Decreased metabolism of Fluconazole caused by Upadacitinib mediated inhibition of CYP450 enzyme. Rheumatoid arthritis [FA20] [164]
Celecoxib DM6LOQU Moderate Decreased metabolism of Fluconazole caused by Celecoxib mediated inhibition of CYP450 enzyme. Rheumatoid arthritis [FA20] [165]
Tofacitinib DMBS370 Major Decreased metabolism of Fluconazole caused by Tofacitinib mediated inhibition of CYP450 enzyme. Rheumatoid arthritis [FA20] [27]
Dexamethasone DMMWZET Moderate Decreased metabolism of Fluconazole caused by Dexamethasone mediated inhibition of CYP450 enzyme. Rheumatoid arthritis [FA20] [26]
Leflunomide DMR8ONJ Major Increased risk of hepatotoxicity by the combination of Fluconazole and Leflunomide. Rheumatoid arthritis [FA20] [25]
Quetiapine DM1N62C Moderate Increased risk of prolong QT interval by the combination of Fluconazole and Quetiapine. Schizophrenia [6A20] [25]
Mesoridazine DM2ZGAN Major Increased risk of prolong QT interval by the combination of Fluconazole and Mesoridazine. Schizophrenia [6A20] [25]
Thioridazine DM35M8J Major Increased risk of prolong QT interval by the combination of Fluconazole and Thioridazine. Schizophrenia [6A20] [25]
Aripiprazole DM3NUMH Moderate Decreased metabolism of Fluconazole caused by Aripiprazole mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [166]
Iloperidone DM6AUFY Major Increased risk of prolong QT interval by the combination of Fluconazole and Iloperidone. Schizophrenia [6A20] [25]
Paliperidone DM7NPJS Moderate Increased risk of prolong QT interval by the combination of Fluconazole and Paliperidone. Schizophrenia [6A20] [25]
Haloperidol DM96SE0 Major Increased risk of prolong QT interval by the combination of Fluconazole and Haloperidol. Schizophrenia [6A20] [25]
Perphenazine DMA4MRX Moderate Increased risk of prolong QT interval by the combination of Fluconazole and Perphenazine. Schizophrenia [6A20] [25]
Chlorpromazine DMBGZI3 Moderate Increased risk of prolong QT interval by the combination of Fluconazole and Chlorpromazine. Schizophrenia [6A20] [25]
Clozapine DMFC71L Major Increased risk of prolong QT interval by the combination of Fluconazole and Clozapine. Schizophrenia [6A20] [25]
Trifluoperazine DMKBYWI Moderate Increased risk of prolong QT interval by the combination of Fluconazole and Trifluoperazine. Schizophrenia [6A20] [25]
Ziprasidone DMM58JY Major Increased risk of prolong QT interval by the combination of Fluconazole and Ziprasidone. Schizophrenia [6A20] [25]
Risperidone DMN6DXL Moderate Increased risk of prolong QT interval by the combination of Fluconazole and Risperidone. Schizophrenia [6A20] [25]
Olanzapine DMPFN6Y Moderate Increased risk of prolong QT interval by the combination of Fluconazole and Olanzapine. Schizophrenia [6A20] [27]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Fluconazole and Amisulpride. Schizophrenia [6A20] [27]
Asenapine DMSQZE2 Moderate Increased risk of prolong QT interval by the combination of Fluconazole and Asenapine. Schizophrenia [6A20] [25]
Pimozide DMW83TP Major Decreased metabolism of Fluconazole caused by Pimozide mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [27]
Fentanyl DM8WAHT Major Decreased metabolism of Fluconazole caused by Fentanyl mediated inhibition of CYP450 enzyme. Sensation disturbance [MB40] [27]
Sufentanil DMU7YEL Moderate Decreased metabolism of Fluconazole caused by Sufentanil mediated inhibition of CYP450 enzyme. Sensation disturbance [MB40] [26]
Avanafil DM75CXN Major Decreased metabolism of Fluconazole caused by Avanafil mediated inhibition of CYP450 enzyme. Sexual dysfunction [HA00-HA01] [167]
Tadalafil DMJZHT1 Moderate Decreased metabolism of Fluconazole caused by Tadalafil mediated inhibition of CYP450 enzyme. Sexual dysfunction [HA00-HA01] [168]
Vardenafil DMTBGW8 Moderate Decreased metabolism of Fluconazole caused by Vardenafil mediated inhibition of CYP450 enzyme. Sexual dysfunction [HA00-HA01] [169]
Voxelotor DMCS6M5 Major Decreased metabolism of Fluconazole caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [170]
LDE225 DMM9F25 Major Decreased metabolism of Fluconazole caused by LDE225 mediated inhibition of CYP450 enzyme. Skin cancer [2C30-2C37] [171]
Gefitinib DM15F0X Moderate Decreased metabolism of Fluconazole caused by Gefitinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [172]
Larotrectinib DM26CQR Moderate Decreased clearance of Fluconazole due to the transporter inhibition by Larotrectinib. Solid tumour/cancer [2A00-2F9Z] [27]
Methylprednisolone DM4BDON Moderate Decreased metabolism of Fluconazole caused by Methylprednisolone mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [26]
Vinblastine DM5TVS3 Moderate Decreased metabolism of Fluconazole caused by Vinblastine mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [26]
Ifosfamide DMCT3I8 Moderate Decreased metabolism of Fluconazole caused by Ifosfamide mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [26]
Docetaxel DMDI269 Moderate Decreased metabolism of Fluconazole caused by Docetaxel mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [173]
Trabectedin DMG3Y89 Moderate Increased risk of hepatotoxicity by the combination of Fluconazole and Trabectedin. Solid tumour/cancer [2A00-2F9Z] [32]
Armodafinil DMGB035 Minor Decreased metabolism of Fluconazole caused by Armodafinil mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [27]
LEE011 DMMX75K Major Increased risk of prolong QT interval by the combination of Fluconazole and LEE011. Solid tumour/cancer [2A00-2F9Z] [25]
Etoposide DMNH3PG Moderate Decreased metabolism of Fluconazole caused by Etoposide mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [26]
Epirubicin DMPDW6T Moderate Increased risk of prolong QT interval by the combination of Fluconazole and Epirubicin. Solid tumour/cancer [2A00-2F9Z] [25]
Prednisolone DMQ8FR2 Moderate Decreased metabolism of Fluconazole caused by Prednisolone mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [26]
Triptorelin DMTK4LS Moderate Increased risk of prolong QT interval by the combination of Fluconazole and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [32]
Norethindrone DMTY169 Moderate Decreased metabolism of Fluconazole caused by Norethindrone mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [76]
Taxol DMUOT9V Moderate Decreased metabolism of Fluconazole caused by Taxol mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [174]
Doxorubicin DMVP5YE Moderate Decreased metabolism of Fluconazole caused by Doxorubicin mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [26]
Vinorelbine DMVXFYE Moderate Decreased metabolism of Fluconazole caused by Vinorelbine mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [26]
Pitolisant DM8RFNJ Moderate Increased risk of prolong QT interval by the combination of Fluconazole and Pitolisant. Somnolence [MG42] [25]
Telavancin DM58VQX Moderate Increased risk of prolong QT interval by the combination of Fluconazole and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [25]
Naltrexone DMUL45H Moderate Increased risk of hepatotoxicity by the combination of Fluconazole and Naltrexone. Substance abuse [6C40] [175]
Warfarin DMJYCVW Major Decreased metabolism of Fluconazole caused by Warfarin mediated inhibition of CYP450 enzyme. Supraventricular tachyarrhythmia [BC81] [65]
Ibutilide DMKXY2R Major Increased risk of prolong QT interval by the combination of Fluconazole and Ibutilide. Supraventricular tachyarrhythmia [BC81] [25]
Adenosine DMM2NSK Moderate Increased risk of ventricular arrhythmias by the combination of Fluconazole and Adenosine. Supraventricular tachyarrhythmia [BC81] [25]
Zithromax DMN4H2O Moderate Increased risk of prolong QT interval by the combination of Fluconazole and Zithromax. Syphilis [1A61-1A6Z] [25]
Fostamatinib DM6AUHV Moderate Decreased metabolism of Fluconazole caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [176]
As-1670542 DMV05SW Major Decreased metabolism of Fluconazole caused by As-1670542 mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [177]
Anagrelide DMSQ8MD Major Increased risk of prolong QT interval by the combination of Fluconazole and Anagrelide. Thrombocytosis [3B63] [25]
Apixaban DM89JLN Moderate Decreased metabolism of Fluconazole caused by Apixaban mediated inhibition of CYP450 enzyme. Thrombosis [DB61-GB90] [32]
Brilinta DMBR01X Moderate Decreased metabolism of Fluconazole caused by Brilinta mediated inhibition of CYP450 enzyme. Thrombosis [DB61-GB90] [32]
Dicumarol DMFQCB1 Major Decreased metabolism of Fluconazole caused by Dicumarol mediated inhibition of CYP450 enzyme. Thrombosis [DB61-GB90] [178]
Clopidogrel DMOL54H Major Decreased metabolism of Fluconazole caused by Clopidogrel mediated inhibition of CYP450 enzyme. Thrombosis [DB61-GB90] [179]
Lenvatinib DMB1IU4 Moderate Increased risk of prolong QT interval by the combination of Fluconazole and Lenvatinib. Thyroid cancer [2D10] [25]
Cabozantinib DMIYDT4 Major Increased risk of prolong QT interval by the combination of Fluconazole and Cabozantinib. Thyroid cancer [2D10] [32]
Papaverine DMCA9QP Major Increased risk of prolong QT interval by the combination of Fluconazole and Papaverine. Tonus and reflex abnormality [MB47] [180]
Tizanidine DMR2IQ4 Moderate Increased risk of prolong QT interval by the combination of Fluconazole and Tizanidine. Tonus and reflex abnormality [MB47] [25]
Trimetrexate DMDEA85 Minor Decreased metabolism of Fluconazole caused by Trimetrexate mediated inhibition of CYP450 enzyme. Toxoplasmosis [1F57] [181]
Sirolimus DMGW1ID Major Decreased metabolism of Fluconazole caused by Sirolimus mediated inhibition of CYP450 enzyme. Transplant rejection [NE84] [182]
Tacrolimus DMZ7XNQ Major Increased risk of prolong QT interval by the combination of Fluconazole and Tacrolimus. Transplant rejection [NE84] [182]
Tolbutamide DM02AWV Major Decreased metabolism of Fluconazole caused by Tolbutamide mediated inhibition of CYP450 enzyme. Type 2 diabetes mellitus [5A11] [30]
Saxagliptin DMGXENV Moderate Decreased metabolism of Fluconazole caused by Saxagliptin mediated inhibition of CYP450 enzyme. Type 2 diabetes mellitus [5A11] [32]
Chlorpropamide DMPHZQE Major Decreased metabolism of Fluconazole caused by Chlorpropamide mediated inhibition of CYP450 enzyme. Type 2 diabetes mellitus [5A11] [30]
Diethylstilbestrol DMN3UXQ Moderate Decreased metabolism of Fluconazole caused by Diethylstilbestrol mediated inhibition of CYP450 enzyme. Vaginitis [GA02] [61]
Fexofenadine DM17ONX Minor Decreased clearance of Fluconazole due to the transporter inhibition by Fexofenadine. Vasomotor/allergic rhinitis [CA08] [183]
Astemizole DM2HN6Q Major Decreased metabolism of Fluconazole caused by Astemizole mediated inhibition of CYP450 enzyme. Vasomotor/allergic rhinitis [CA08] [36]
Triamcinolone DM98IXF Moderate Decreased metabolism of Fluconazole caused by Triamcinolone mediated inhibition of CYP450 enzyme. Vasomotor/allergic rhinitis [CA08] [26]
Trimeprazine DMEMV9D Moderate Increased risk of prolong QT interval by the combination of Fluconazole and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [148]
Fluticasone DMGCSVF Moderate Decreased metabolism of Fluconazole caused by Fluticasone mediated inhibition of CYP450 enzyme. Vasomotor/allergic rhinitis [CA08] [27]
Disopyramide DM5SYZP Major Increased risk of prolong QT interval by the combination of Fluconazole and Disopyramide. Ventricular tachyarrhythmia [BC71] [25]
Propafenone DMPIBJK Moderate Increased risk of prolong QT interval by the combination of Fluconazole and Propafenone. Ventricular tachyarrhythmia [BC71] [25]
Flecainide DMSQDLE Moderate Increased risk of prolong QT interval by the combination of Fluconazole and Flecainide. Ventricular tachyarrhythmia [BC71] [25]
Amiodarone DMUTEX3 Major Decreased metabolism of Fluconazole caused by Amiodarone mediated inhibition of CYP450 enzyme. Ventricular tachyarrhythmia [BC71] [184]
⏷ Show the Full List of 413 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Allura red AC dye E00338 33258 Colorant
Kyselina citronova E00014 311 Acidulant; Antioxidant; Buffering agent; Complexing agent; Flavoring agent
Quinoline yellow WS E00309 24671 Colorant
Silotermo carmine G E00611 135487652 Colorant
Sodium benzoate E00432 517055 Antimicrobial preservative; lubricant
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Calcium hydrogenphosphate E00294 24441 Diluent
Carmellose sodium E00625 Not Available Disintegrant
Dextrose monohydrate E00538 22814120 Binding agent; Diluent; Flavoring agent; Tonicity agent
Eisenoxyd E00585 56841934 Colorant
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Povidone E00667 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sodium citrate dihydrate E00369 71474 Alkalizing agent; Buffering agent; Complexing agent; Emulsifying agent
Sucrose 1,6-distearate E00593 71587490 Dispersing agent; Emulsifying agent; Modified-release agent; Solubilizing agent; Surfactant; lubricant
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Vinylpyrrolidone E00668 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Water E00035 962 Solvent
⏷ Show the Full List of 21 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Fluconazole 100 mg tablet 100 mg Oral Tablet Oral
Fluconazole 150 mg tablet 150 mg Oral Tablet Oral
Fluconazole 50 mg tablet 50 mg Oral Tablet Oral
Fluconazole 200 mg tablet 200 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Fluconazole use as an important risk factor in the emergence of fluconazole-resistant Candida glabrata fungemia. Arch Intern Med. 2009 Aug 10;169(15):1444-5; author reply 1445.
2 FDA Approved Drug Products: Diflucan (fluconazole)
3 BDDCS applied to over 900 drugs
4 Pichette V, du Souich P: Role of the kidneys in the metabolism of furosemide: its inhibition by probenecid. J Am Soc Nephrol. 1996 Feb;7(2):345-9.
5 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
7 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
8 Effect of fluconazole on plasma fluvastatin and pravastatin concentrations. Eur J Clin Pharmacol. 2000 Jun;56(3):225-9.
9 Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
10 Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother. 2006 Aug;18(4):421-4.
11 Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
12 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
13 Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076.
14 Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
15 New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
16 A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
17 A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
18 A new, broad-spectrum azole antifungal: posaconazole--mechanisms of action and resistance, spectrum of activity. Mycoses. 2006;49 Suppl 1:2-6.
19 Clinical pharmacokinetics and pharmacodynamics of solifenacin. Clin Pharmacokinet. 2009;48(5):281-302.
20 Antifungal agents: mechanisms of action. Trends Microbiol. 2003 Jun;11(6):272-9.
21 Mode of action of anti-Candida drugs: focus on terconazole and other ergosterol biosynthesis inhibitors. Am J Obstet Gynecol. 1991 Oct;165(4 Pt 2):1193-9.
22 Investigation of the role of cytochrome P450 2B4 active site residues in substrate metabolism based on crystal structures of the ligand-bound enzyme. Arch Biochem Biophys. 2006 Nov 1;455(1):61-7.
23 Biological spectra analysis: Linking biological activity profiles to molecular structure. Proc Natl Acad Sci U S A. 2005 Jan 11;102(2):261-6.
24 Differential azole antifungal efficacies contrasted using a Saccharomyces cerevisiae strain humanized for sterol 14 alpha-demethylase at the homolo... Antimicrob Agents Chemother. 2008 Oct;52(10):3597-603.
25 Canadian Pharmacists Association.
26 Assan R, Fredj G, Larger E, Feutren G, Bismuth H "FK 506/fluconazole interaction enhances FK 506 nephrotoxicity." Diabete Metab 20 (1994): 49-52. [PMID: 7520007]
27 Cerner Multum, Inc. "Australian Product Information.".
28 Caballero-Granado FJ, Viciana P, Cordero E, Gomez-Vera MJ, del Nozal M, Lopez-Cortes LF "Ergotism related to concurrent administration of ergotamine tartrate and ritonavir in an AIDS patient." Antimicrob Agents Chemother 41 (1997): 1207. [PMID: 9145904]
29 Adamson PC "Pharmacokinetics of all-trans-retinoic acid: clinical implications in acute promyelocytic leukemia." Semin Hematol 31 (1994): 14-7. [PMID: 7831580]
30 Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7. [PMID: 11678792]
31 Bidstrup TB, Bjornsdottir I, Sidelmann UG, Thomsen MS, Hansen KT "CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide." Br J Clin Pharmacol 56 (2003): 305-14. [PMID: 12919179]
32 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
33 Product Information. Aubagio (teriflunomide). Genzyme Corporation, Cambridge, MA.
34 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
35 Dutreix C, Munarini F, Lorenzo S, Roesel J, Wang Y "Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers." Cancer Chemother Pharmacol 72 (2013): 1223-34. [PMID: 24085261]
36 Ament PW, Paterson A "Drug interactions with the nonsedating antihistamines." Am Fam Physician 56 (1997): 223. [PMID: 9225677]
37 Product Information. Claritin (loratadine). Schering Laboratories, Kenilworth, NJ.
38 Product Information. Aricept (donepezil). Pfizer US Pharmaceuticals, New York, NY.
39 Product Information. Ranexa (ranolazine). Calmoseptine Inc, Huntington Beach, CA.
40 Heinig R, Adelmann HG, Ahr G "The effect of ketoconazole on the pharmacokinetics, pharmacodynamics and safety of nisoldipine." Eur J Clin Pharmacol 55 (1999): 57-60. [PMID: 10206086]
41 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
42 Kivisto KT, Lamberg TS, Kantola T, Neuvonen PJ "Plasma buspirone concentrations are greatly increased by erythromycin and itraconazole." Clin Pharmacol Ther 62 (1997): 348-54. [PMID: 9333111]
43 Ahonen J, Olkkola KT, Neuvonen PJ "Effect of itraconazole and terbinafine on the pharmacokinetics and pharmacodynamics of midazolam in healthy volunteers." Br J Clin Pharmacol 40 (1995): 270-2. [PMID: 8527290]
44 Product Information. Onfi (clobazam). Lundbeck Inc, Deerfield, IL.
45 Product Information. Diflucan (fluconazole). Roerig Division, New York, NY.
46 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
47 Karonen T, Filppula A, Laitila J, Niemi M, Neuvonen PJ, Backman JT "Gemfibrozil Markedly Increases the Plasma Concentrations of Montelukast: A Previously Unrecognized Role for CYP2C8 in the Metabolism of Montelukast." Clin Pharmacol Ther (2010):. [PMID: 20592724]
48 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
49 Bolland MJ, Bagg W, Thomas MG, Lucas JA, Ticehurst R, Black PN "Cushing's syndrome due to interaction between inhaled corticosteroids and itraconazole." Ann Pharmacother 38 (2004): 46-9. [PMID: 14742792]
50 Product Information. Elidel (pimecrolimus topical). Novartis Pharmaceuticals, East Hanover, NJ.
51 Dorsey ST, Biblio LA "Prolonged QT interval and torsades de pointes caused by the combination of fluconazole and amitriptyline." Am J Emerg Med 18 (2000): 227-9. [PMID: 10750939]
52 Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
53 Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004): 55-6. [PMID: 14722399]
54 Product Information. Vraylar (cariprazine). Actavis Pharma, Inc., Parsippany, NJ.
55 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
56 Eggleston W, Clark KH, Marraffa JM "Loperamide abuse associated with cardiac dysrhythmia and death." Ann Emerg Med 69 (2017): 83-6. [PMID: 27140747]
57 Product Information. Ixempra (ixabepilone). Bristol-Myers Squibb, Princeton, NJ.
58 Product Information. Tykerb (lapatinib). Novartis Pharmaceuticals, East Hanover, NJ.
59 Abbas R, Hug BA, Leister C, Burns J, Sonnichsen D "Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects." Br J Clin Pharmacol 71 (2011): 522-7. [PMID: 21395644]
60 Product Information. Verzenio (abemaciclib). Lilly, Eli and Company, Indianapolis, IN.
61 Devenport MH, Crook D, Wynn V, Lees LJ "Metabolic effects of low-dose fluconazole in healthy female users and non-users of oral contraceptives." Br J Clin Pharmacol 27 (1989): 851-9. [PMID: 2547410]
62 Product Information. Jevtana (cabazitaxel). sanofi-aventis , Bridgewater, NJ.
63 Akram K, Rao S, Parker M "A lesson for everyone in drug-drug interactions." Int J Cardiol 118 (2007): e19-20. [PMID: 17368833]
64 Product Information. Opsumit (macitentan). Actelion Pharmaceuticals US Inc, South San Francisco, CA.
65 Baciewicz AM, Menke JJ, Bokar JA, Baud EB "Fluconazole-warfarin interaction." Ann Pharmacother 28 (1994): 1111. [PMID: 7803894]
66 Hanci V, Aydin M, Yurtlu BS, et.al "Anesthesia induction with sevoflurane and propofol: evaluation of P-wave dispersion, QT and corrected QT intervals." Kaohsiung J Med Sci 26 (2010): 470-7. [PMID: 20837343]
67 Ekstrom G, Gunnarsson UB "Ropivacaine, a new amide-type local anesthetic agent, is metabolized by cytochromes P450 1A and 3A in human liver microsomes." Drug Metab Dispos 24 (1996): 955-61. [PMID: 8886604]
68 Bartkowski RR, Goldberg ME, Larijani GE, Boerner T "Inhibition of alfentanil metabolism by erythromycin." Clin Pharmacol Ther 46 (1989): 99-102. [PMID: 2501060]
69 Product Information. Lamprene (clofazimine). Novartis Pharmaceuticals, East Hanover, NJ.
70 Product Information. Emend (aprepitant). Merck & Company Inc, West Point, PA.
71 Product Information. Viibryd (vilazodone). Trovis Pharmaceuticals LLC, New Haven, CT.
72 Product Information. Rexulti (brexpiprazole). Otsuka American Pharmaceuticals Inc, Rockville, MD.
73 Antonelli D, Atar S, Freedberg NA, Rosenfeld T "Torsade de pointes in patients on chronic amiodarone treatment: contributing factors and drug interactions." Isr Med Assoc J 7 (2005): 163-5. [PMID: 15792261]
74 Okubo M, Murayama N, Miura J, Chiba Y, Yamazaki H "Effects of cytochrome P450 2D6 and 3A5 genotypes and possible coadministered medicines on the metabolic clearance of antidepressant mirtazapine in Japanese patients." Biochem Pharmacol 93 (2015): 104-9. [PMID: 25475885]
75 Product Information. Polivy (polatuzumab vedotin). Genentech, South San Francisco, CA.
76 Lazar JD, Wilner KD "Drug interactions with fluconazole." Rev Infect Dis 12 Suppl 3 (1990): s327-33. [PMID: 2330488]
77 Product Information. Osphena (ospemifene). Shionogi USA Inc, Florham Park, NJ.
78 Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
79 Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
80 Ahonen J, Olkkola KT, Neuvonen PJ "The effect of the antimycotic itraconazole on the pharmacokinetics and pharmacodynamics of diazepam." Fundam Clin Pharmacol 10 (1996): 314-8. [PMID: 8836707]
81 Nakasa H, Nakamura H, Ono S, Tsutsui M, Kiuchi M, Ohmori S, Kitada M "Prediction of drug-drug interactions of zonisamide metabolism in humans from in vitro data." Eur J Clin Pharmacol 54 (1998): 177-83. [PMID: 9626925]
82 Blum RA, Wilton JH, Hilligoss DM, et al "Effect of fluconazole on the disposition of phenytoin." Clin Pharmacol Ther 49 (1991): 420-5. [PMID: 2015731]
83 Klotz U "The role of pharmacogenetics in the metabolism of antiepileptic drugs: pharmacokinetic and therapeutic implications." Clin Pharmacokinet 46 (2007): 271-9. [PMID: 17375979]
84 Product Information. Aliqopa (copanlisib). Bayer Pharmaceutical Inc, West Haven, CT.
85 Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
86 Product Information. VESIcare (solifenacin). GlaxoSmithKline, Research Triangle Park, NC.
87 Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
88 Brynne N, Forslund C, Hallen B, Gustafsson LL, Bertilsson L "Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activity." Br J Clin Pharmacol 48 (1999): 564-72. [PMID: 10583027]
89 Product Information. Enablex (darifenacin). Novartis Pharmaceuticals, East Hanover, NJ.
90 Bedford TA, Rowbotham DJ "Cisapride: drug interactions of clinical significance." Drug Saf 15 (1996): 167-75. [PMID: 8879971]
91 Akdag I, Ersoy A, Kahvecioglu S, Gullulu M, Dilek K "Acute colchicine intoxication during clarithromycin administration in patients with chronic renal failure." J Nephrol 19 (2006): 515-7. [PMID: 17048210]
92 Ausband SC, Goodman PE "An unusual case of clarithromycin associated ergotism." J Emerg Med 4 (2001): 411-3. [PMID: 11728770]
93 Product Information. Inspra (eplerenone). Searle, Chicago, IL.
94 Product Information. Coreg (carvedilol). SmithKline Beecham, Philadelphia, PA.
95 Miners JO, Rees DLP, Valente L, Veronese ME, Birkett DJ "Human hepatic cytochrome p450 2c9 catalyzes the rate-limiting pathway of torsemide metabolism." J Pharmacol Exp Ther 272 (1995): 1076-81. [PMID: 7891318]
96 Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
97 Product Information. Pifeltro (doravirine). Merck & Company Inc, Whitehouse Station, NJ.
98 Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov). Gilead Sciences, Foster City, CA.
99 Product Information. Aptivus (tipranavir). Boehringer-Ingelheim, Ridgefield, CT.
100 Product Information. Sustiva (efavirenz). DuPont Pharmaceuticals, Wilmington, DE.
101 Product Information. Tivicay (dolutegravir). ViiV Healthcare, Research Triangle Park, NC.
102 Koks CH, Crommentuyn KM, Hoetelmans RM, et al. "The effect of fluconazole on ritonavir and saquinavir pharmacokinetics in HIV-1-infected individuals." Br J Clin Pharmacol 51 (2001): 631-5. [PMID: 11422025]
103 Product Information. Edurant (rilpivirine). Tibotec Pharmaceuticals, Titusville, NJ.
104 Product Information. Agenerase (amprenavir). Glaxo Wellcome, Research Triangle Pk, NC.
105 Product Information. Selzentry (maraviroc). Pfizer U.S. Pharmaceuticals Group, New York, NY.
106 Cato A 3rd, Cao G, Hsu A, Cavanaugh J, Leonard J, Granneman R "Evaluation of the effect of fluconazole on the pharmacokinetics of ritonavir." Drug Metab Dispos 25 (1997): 1104-6. [PMID: 9311629]
107 Kantola T, Backman JT, Niemi M, Kivisto KT, Neuvonen PJ "Effect of fluconazole on plasma fluvastatin and pravastatin concentrations." Eur J Clin Pharmacol 56 (2000): 225-9. [PMID: 10952477]
108 Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
109 Kazierad DJ, Martin DE, Tenero D, et al. "Fluconazole significantly alters the pharmacokinetics of losartan but not eprosartan." Clin Pharmacol Ther 61 (1997): 203. [PMID: 9357393]
110 Product Information. Samsca (tolvaptan). Otsuka American Pharmaceuticals Inc, Rockville, MD.
111 Product Information. Altabax (retapamulin topical). GlaxoSmithKline, Research Triangle Park, NC.
112 Product Information. Zurampic (lesinurad). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
113 Product Information. Belsomra (suvorexant). Merck & Company Inc, Whitehouse Station, NJ.
114 Product Information. Rozerem (ramelteon). Takeda Pharmaceuticals America, Lincolnshire, IL.
115 Alderman CP, Gebauer MG, Gilbert AL, Condon JT "Possible interaction of zopiclone and nefazodone." Ann Pharmacother 35 (2001): 1378-80. [PMID: 11724087]
116 Product Information. Hetlioz (tasimelteon). Vanda Pharmaceuticals Inc, Rockville, MD.
117 Product Information. Caplyta (lumateperone). Intra-Cellular Therapies, Inc., New York, NY.
118 Product Information. Viberzi (eluxadoline). Actavis Pharma, Inc., Parsippany, NJ.
119 Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
120 Product Information. Zepzelca (lurbinectedin). Jazz Pharmaceuticals, Palo Alto, CA.
121 Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
122 Product Information. Gavreto (pralsetinib). Blueprint Medicines Corporation, Cambridge, MA.
123 Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
124 Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
125 Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
126 Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
127 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
128 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
129 Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
130 Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
131 Product Information. Clolar (clofarabine). sanofi-aventis, Bridgewater, NJ.
132 Product Information. Imbruvica (ibrutinib). Pharmacyclics Inc, Sunnyvale, CA.
133 Product Information. Iclusig (ponatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
134 Product Information. Koselugo (selumetinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
135 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
136 Product Information. Ubrelvy (ubrogepant). Allergan Inc, Irvine, CA.
137 Product Information. Nurtec ODT (rimegepant). Biohaven Pharmaceuticals, New Haven, CT.
138 Product Information. Relpax (eletriptan). Pfizer U.S. Pharmaceuticals, New York, NY.
139 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
140 Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
141 Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
142 Jordan MK, Polis MA, Kelly G, Narang PK, Masur H, Piscitelli SC "Effects of fluconazole and clarithromycin on rifabutin and 25-O-desacetylrifabutin pharmacokinetics." Antimicrob Agents Chemother 44 (2000): 2170-72. [PMID: 10898693]
143 Product Information. Gleevec (imatinib mesylate). Novartis Pharmaceuticals, East Hanover, NJ.
144 Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
145 Product Information. Meridia (sibutramine). Knoll Pharmaceutical Company, Whippany, NJ.
146 Product Information. Orlaam (levomethadyl acetate) Roxanne Laboratories Inc, Columbus, OH.
147 Product Information. Bextra (valdecoxib). Pharmacia Corporation, Peapack, NJ.
148 Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8. [PMID: 12904146]
149 Product Information. Butorphanol Tartrate (butorphanol). Apotex Corporation, Weston, FL.
150 Product Information. Buprenex (buprenorphine). Reckitt and Colman Pharmaceutical, Richmond, VA.
151 Hutchinson MR, Menelaou A, Foster DJ, Coller JK, Somogyi AA "CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes." Br J Clin Pharmacol 57 (2004): 287-97. [PMID: 14998425]
152 Product Information. Nourianz (istradefylline). Kyowa Kirin, Inc, Bedminster, NJ.
153 Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
154 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
155 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
156 Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
157 Product Information. Nubeqa (darolutamide). Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.
158 Franco-Salinas G, de la Rosette JJ, Michel MC "Pharmacokinetics and pharmacodynamics of tamsulosin in its modified-release and oral controlled absorption system formulations." Clin Pharmacokinet 49 (2010): 177-88. [PMID: 20170206]
159 Product Information. Rapaflo (silodosin). Watson Pharmaceuticals, Corona, CA.
160 Product Information. Duagen (dutasteride). GlaxoSmithKline Healthcare, Pittsburgh, PA.
161 Product Information. Letairis (ambrisentan). Gilead Sciences, Foster City, CA.
162 Product Information. Afinitor (everolimus). Novartis Pharmaceuticals, East Hanover, NJ.
163 Product Information. Torisel (temsirolimus). Wyeth-Ayerst Laboratories, Philadelphia, PA.
164 Product Information. Rinvoq (upadacitinib). AbbVie US LLC, North Chicago, IL.
165 Product Information. Celebrex (celecoxib). Searle, Chicago, IL.
166 Product Information. Abilify (aripiprazole). Bristol-Myers Squibb, Princeton, NJ.
167 Product Information. Stendra (avanafil). Vivus Inc, Mountain View, CA.
168 Product Information. Cialis (tadalafil). Lilly, Eli and Company, Indianapolis, IN.
169 Product Information. Levitra (vardenafil). Bayer, West Haven, CT.
170 Product Information. Oxbryta (voxelotor). Global Blood Therapeutics, Inc., South San Francisco, CA.
171 Product Information. Odomzo (sonidegib). Novartis Pharmaceuticals, East Hanover, NJ.
172 Li J, Zhao M, He P, Hidalgo M, Baker SD "Differential metabolism of gefitinib and erlotinib by human cytochrome p450 enzymes." Clin Cancer Res 13 (2007): 3731-7. [PMID: 17575239]
173 Aronson JK, Grahame-Smith DG "Clinical pharmacology: adverse drug interactions." Br Med J 282 (1981): 288-91. [PMID: 6779990]
174 Bergmann TK, Filppula AM, Launiainen T, Nielsen F, Backman J, Brosen K "Neurotoxicity and low paclitaxel clearance associated with concomitant clopidogrel therapy in a 60 year old Caucasian woman with ovarian carcinoma." Br J Clin Pharmacol (2015):. [PMID: 26446447]
175 Product Information. ReVia (naltrexone). DuPont Pharmaceuticals, Wilmington, DE.
176 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
177 Nomo, Zamora, Schuck, et al. "Pharmacokinetic/pharmacodynamic drug-drug interactions of avatrombopag when coadministered with dual or selective CYP2C9 and CYP3A interacting." PubMed 84 (2018): 1. [PMID: 29341245]
178 Holechek MJ "Medication review: fluconazole." ANNA J 18 (1991): 585-6. [PMID: 1750792]
179 Collet JP, Hulot JS, Pena A, et al. "Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study." Lancet 373 (2009): 309-17. [PMID: 19108880]
180 Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]
181 Product Information. Neutrexin (trimetrexate). US Bioscience, West Conshohocken, PA.
182 Albengres E, Le Louet H, Tillement JP "Systemic antifungal agents. Drug interactions of clinical significance." Drug Saf 18 (1998): 83-97. [PMID: 9512916]
183 Product Information. Allegra (fexofenadine). Hoechst Marion-Roussel Inc, Kansas City, MO.
184 Fabre G, Julian B, Saint-Aubert B, Joyeux H, Berger Y "Evidence for CYP3A-mediated N-deethylation of amiodarone in human liver microsomal fractions." Drug Metab Dispos 21 (1993): 978-85. [PMID: 7905403]